Chávarri-Guerra, Y, Bourlon, MT, Rodríguez-Olivares, JL, Orozco, L, Bazua, D, Rodríguez-Faure, A, Alcalde-Castro, MJ, Castro, E, Castillo, D, Herzog, J, Weitzel, J (2023).
Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer
CLINICAL GENITOURINARY CANCER. Article. 21(5):569-573.
[doi:10.1016/j.clgc.2023.05.012]
Beije, N, Abida, W, Antonarakis, ES, Castro, E, de Wit, R, Fizazi, K, Gillessen, S, Hussain, M, Mateo, J, Morris, MJ, Olmos, D, Sartor, O, Sharp, A, Sweeney, CJ, de Bono, JS (2023).
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
EUROPEAN UROLOGY. Editorial Material. 84(3):253-256.
[doi:10.1016/j.eururo.2023.03.038]
Chi, KN, Sandhu, S, Smith, MR, Attard, G, Saad, M, Olmos, D, Castro, E, Roubaud, G, Gomes, AJPD, Small, EJ, Rathkopf, DE, Gurney, H, Jung, W, Mason, GE, Dibaj, S, Wu, D, Diorio, B, Urtishak, K, del Corral, A, Francis, P, Kim, W, Efstathiou, E (2023).
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
ANNALS OF ONCOLOGY. Article. 34(9):772-782.
[doi:10.1016/j.annonc.2023.06.009]
Smith, MR, Sandhu, S, George, DJ, Chi, KN, Saad, F, Thiery-Vuillemin, A, Stáhl, O, Olmos, D, Danila, DC, Gafanov, R, Castro, E, Moon, H, Joshua, AM, Mason, GE, Espina, BM, Liu, Y, Lopez-Gitlitz, A, Francis, P, Bevans, KB, Fizazi, K (2023).
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
Journal of Managed Care & Specialty Pharmacy. Article. 29(7):758-768.
